Securities Code: 300254
Securities Abbreviation: Qianyuan Pharmaceutical
Announcement No.: 2026-072
Shanxi Qianyuan Pharmaceutical Group Co., Ltd.
Resolution Announcement of the Seventh Meeting of the Sixth Board of Directors
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
Shanxi Qianyuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") sent out the notice and proposals for the seventh meeting of the sixth Board of Directors via email on August 14, 2026. The meeting was held via written voting on August 17, 2026. The meeting was presided over by Chairman Huang Lequn. Seven directors were expected to attend, and seven directors actually attended. All attendees raised no objections to the convening and voting method of the meeting. The convening and holding of this meeting comply with the relevant provisions of the "Company Law," "Articles of Association," and "Rules of Procedure for Board Meetings."
II. Deliberation of the Board Meeting
All directors attending the meeting carefully deliberated on the proposals and approved the following proposals by voting:
- Proposal on the Approval of the "Proposal on the 2026 Restricted Stock Incentive Plan (Draft) and its Summary"
To further establish and improve the Company's long-term incentive mechanism, attract and retain outstanding talents, fully mobilize the enthusiasm of directors, senior management, and core backbone personnel, effectively align shareholder interests, company interests, and the personal interests of the core team, so that all parties jointly focus on the Company's long-term development, and enhance the Company's market competitiveness and sustainable development capabilities. Under the premise of fully protecting shareholder interests, and in accordance with the principle of equal rewards and contributions, the Company, based on relevant laws, regulations, and normative documents such as the "Company Law," "Securities Law of the People's Republic of China," "Administrative Measures for Equity Incentives of Listed Companies," "Listing Rules of the Shenzhen Stock Exchange for GEM Companies," and "GEM Listed Company Self-Regulatory Guidance No. 1 - Business Handling," and the "Articles of Association," and in conjunction with the Company's actual situation, the Company's Board of Directors' Compensation and Appraisal Committee has formulated the "Shanxi Qianyuan Pharmaceutical Group Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft)" and its summary in accordance with relevant laws and regulations.
For specific content, please refer to the "Proposal on the 2026 Restricted Stock Incentive Plan (Draft) and its Summary" released on the information disclosure website designated by the China Securities Regulatory Commission.
Voting Result: 5 votes in favor, 0 votes against, 0 abstentions.
Related directors Huang Lequn and Zhong Haisheng participated in this equity incentive plan and abstained from voting on this proposal.
This proposal needs to be submitted to the Company's 2026 Third Extraordinary General Meeting for deliberation.
- Proposal on the Approval of the "Proposal on the Management Measures for the Implementation and Assessment of the 2026 Restricted Stock Incentive Plan"